Brilliant Peel®

BIOMATERIALS

Brilliant Peel®

Heavy dye for selective staining

  • Selective staining of the ILM
  • Negative staining of the ERM and of residual vitreous fragments
  • Quick and intensive staining due to the sinking of the dye
  • Biocompatible solution for identifying residual ILM fragment
  • Without preserving agents

Vial G-81010 Brilliant Peel® 0,5 ml, sterile
Syringe G-81005 Brilliant Peel® 0,5 ml, sterile

Brilliant-peelBrilliant-peel
Brilliant-peelBrilliant-peel

Product Information

Overview

Composition and properties of Brilliant Peel®

Composition of one 0.5 ml syringe / vial:0,125 mg Brilliant Blue G0,95 mg Na2HPO4 x 2 H2O0,15 mg NaH2PO4 x 2 H2O4,1 mg NaCl0,065 ml D2Oad 0,5 ml water for injection purposesConcentration:0,25 g/l Brilliant Blue GDensity:1,02 g/cm3

Use

Brilliant Peel® was developed for specific staining of the inner limiting membrane(ILM). Specific staining of the ILM allows it to be clearly differentiated from the underlying retinal tissue and the epiretinal membranes. The surgically demanding removal of the ILM thus becomes easier and safer.

Literature:

1 Lüke C, et al.: Retinal tolerance to dyes, Br J Ophthalmol, 2005, 89, 1188-11912 Haritoglou C, et al.: Färbetechniken in der Makulachirurgie, Ophthalmologe, 2006, 103, 927-9343 Ueno A, et al.: Biocompatibility of Brilliant Blue G in a rat model of subretinal injection, Retina, 2007, 27, 499-5044 Enaida H, et al.: Brilliant Blue G selectively stains the internal limiting membrane – Brilliant Blue G assisted membrane peeling, Retina, 2006, 26, 631 – 6365 Enaida H, et al.: Preclinical investigation of internal limiting membrane staining and peeling using intra­vitreal Brilliant Blue G, Retina, 2006, 26, 623-6306 Hisatomi T, et al.: Staining ability and biocompatibility of Brilliant Blue G – preclinical study of Brilliant Blue G as an adjunct for capsular staining, Arch Ophthalmol, 2006, 124, 514-5197 Goldman JM, et al.: Adjunct devices for managing challenging cases in cataract surgery – capsular staining and ophthalmic viscosurgical devices, Curr Opin Ophthalmol, 2007, 18, 52-578 Meyer CH, et al.: Historical considerations in applying vital dyes in vitreoretinal surgery: from early experiments to advanced chromovitrectomy, Expert Rev.Ophthalmol., 2007, 71-779 Hiebl W, et al.: Substances for staining biological tissues: use of dyes in ophthalmology, Klin Monatsbl Augenh, 2005, 222, 309-31110 Frank Schuettauf, Christos Haritoglou, Christian A. May, Robert Rejdak, Anna Mankowska, Wolfgang Freyer, Kirsten Eibl, Eberhart Zrenner, Anselm Kampik and Sebastian Thaler, Administration of Novel Dyes for Intra­ocular Surgery: An In Vivo Toxicity Animal Study, Invest Ophthalmol Vis Sci. 2006; 47:3573–357811 Rodrigues EB, et al.: Vital dyes for chromovitrectomy, Curr Opin Ophthalmol, 2007 May; 18(3):179-8712 Furlani BA, et al.: Lutein and zeaxanthin toxicity with and without brilliant blue in rabbits. J Ocul Pharmacol Ther. 2014 Sep; 30(7):559-66. doi: 10.1089/jop.2013.0171. Epub 2014 Jun 5.13 Tura A, et al.: Testing the effects of the dye acid violet-17 on retinal function for an intraocular application in vitreo-retinal surgery. Graefes Arch Clin Exp Opthalmol. 2014 Dec; 252(12):1927-37. doi: 10.1007/s00417-014-2761-9. Epub 2014 Sep 14.14 Patent DE102012103097 A115 Sousa-Martins D, et al.: Use of lutein and zeaxanthin alone or combined with Brilliant Blue to identify intra­ocular structures intraoperatively. Retina. 2012 Jul; 32(7):1328-36. doi: 10.1097/IAE.0b013e318239e2b6.

Read More

Download PDF

Related Products

Skip to content